The Porphyria (Erythropoietic Protoporphyri) drugs in development market research report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Porphyria (Erythropoietic Protoporphyri). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Porphyria (Erythropoietic Protoporphyri) by eight companies/universities/institutes. The top development phase for Porphyria (Erythropoietic Protoporphyri) is preclinical with four drugs in that stage. The Porphyria (Erythropoietic Protoporphyri) pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Porphyria (Erythropoietic Protoporphyri) pipeline products market are: ATLAS Molecular Pharma, Ractigen Therapeutics and Mitsubishi Tanabe Pharma.

The key targets in the Porphyria (Erythropoietic Protoporphyri) pipeline products market include Porphobilinogen Deaminase (Hydroxymethylbilane Synthase or Pre Uroporphyrinogen Synthase or PBGD or HMBS or EC, Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R), and Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9).

The key mechanisms of action in the Porphyria (Erythropoietic Protoporphyri) pipeline product include Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Agonist with two drugs in Phase III. The Porphyria (Erythropoietic Protoporphyri) pipeline products include three routes of administration with the top ROA being Oral and six key molecule types in the Porphyria (Erythropoietic Protoporphyri) pipeline products market including Small Molecule, and Synthetic Peptide.

Porphyria (Erythropoietic Protoporphyri) overview

Erythropoietic protoporphyria (EPP) is an inherited porphyria caused by the accumulation of protoporphyrins in red blood cells that causes acute, painful photosensitivity and potential liver disease. It usually occurs in early childhood with immediate pain and crying upon exposure to bright sunlight. It is a lifelong disease, and repeated phototoxic reactions eventually lead to thickening of the skin and wax-like scarring on the face.

For a complete picture of Porphyria (Erythropoietic Protoporphyri)’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.